Pfizer Inc.

NYSE:PFE  
37.25
+0.72 (+1.97%)
4:24:46 PM EDT: $37.27 +0.02 (+0.05%)
Products

Vivet Therapeutics, Pfizer Announce FDA Authorization To Proceed With Gateway, The Phase 1/2 Study For VTX-801

Published: 11/18/2020 06:07 GMT
Pfizer Inc (PFE) - Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed With Gateway, the Phase 1/2 Study for Vtx-801, Vivet’s Investigational Gene Therapy for Wilson Disease.
Vivet Therapeutics- Trial for Phase 1/2 Study for Vtx-801 is Expected to Commence in Early 2021.